Retatrutide Dosage Calculator

What Is Retatrutide?

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. In clinical trials, it has shown significant potential for weight loss and metabolic improvement. It is administered as a weekly subcutaneous injection.

⚠️ Important: Retatrutide is an investigational drug. This calculator is based on published clinical trial data and is for educational purposes only. Always follow your healthcare provider's dosing instructions.

Titration Schedule

Phase 3 Trial Titration (12mg target):
Weeks 1-4: 1 mg/week
Weeks 5-8: 2 mg/week
Weeks 9-12: 4 mg/week
Weeks 13-16: 8 mg/week
Weeks 17+: 12 mg/week (maintenance)

How It Works

Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP), retatrutide targets three receptors, potentially providing enhanced metabolic benefits through increased energy expenditure, reduced appetite, and improved glucose metabolism.

How to Use

Select your target dose and current week. The calculator shows your current titration dose and schedule.

Common Side Effects

Nausea, diarrhea, vomiting, and constipation are common, especially during dose escalation. Gradual titration helps minimize these effects.

Disclaimer

This calculator is for educational purposes only. Retatrutide has not been FDA-approved. Never self-medicate with research compounds. Consult your healthcare provider.

Frequently Asked Questions

An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors for weight management.

Retatrutide targets three receptors (GLP-1, GIP, glucagon) vs semaglutide which targets only GLP-1.

In clinical trials, doses up to 12 mg weekly were studied.

No, retatrutide is still in clinical trials and has not been approved by the FDA.

Gradual dose increases allow your body to adjust, minimizing gastrointestinal side effects.

In clinical trials, participants lost up to 24% of body weight over 48 weeks at the highest dose.